相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Pegylated arginase I: a potential therapeutic approach in T-ALL
Claudia P. Hernandez et al.
BLOOD (2010)
Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma
Evan S. Glazer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)
Sam-Mui Tsui et al.
CANCER CELL INTERNATIONAL (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
A New Prognostic Score System in Patients With Advanced Hepatocellular Carcinoma Not Amendable to Locoregional Therapy Implication for Patient Selection in Systemic Therapy Trials
Thomas Yau et al.
CANCER (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion
Paul Ning-Man Cheng et al.
CANCER RESEARCH (2007)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
PA Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma
PNM Cheng et al.
CANCER LETTERS (2005)
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation
BJ Dillon et al.
CANCER (2004)
Systemic therapies for hepatocellular carcinoma
DH Palmer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
J Bruix et al.
JOURNAL OF HEPATOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)